A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis

• Status: Completed
• Trial end date: 2020-04-28
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and tolerability of KA34 when administered via intra-articular injection to subjects with osteoarthritis of the knee.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Calibr, a division of Scripps Research; California Institute for Biomedical Research
• Collaborator: California Institute for Regenerative Medicine (CIRM)

Criteria

Inclusion Criteria:

• Diagnosis of localized osteoarthritis of the knee

• Males willing to use contraception and females who are no longer able to bear children

Exclusion Criteria:

• Body Mass Index (BMI) > 40

• Grade 0, 3 or 4 osteoarthritis on the Kellgren and Lawrence classification system

• Injury to the knee or other joint within the last 12 months

• Receipt of any investigational product or experimental therapeutic procedure within the last 12 weeks